Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Statistics
  • Help & Advice
University of Warwick

The Library

  • Login

The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains

Tools
- Tools
+ Tools

UNSPECIFIED. (2006) The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains. LEUKEMIA & LYMPHOMA, 47 (1). pp. 21-28. ISSN 1042-8194

Full text not available from this repository.
Official URL: http://dx.doi.org/10.1080/10428190500254216

Abstract

In multiple myeloma, changes in serum-free immunoglobulin light chains (FLC) are a more rapid indicator of treatment response than intact immunoglobulin due to their shorter serum half-life. The present study analysed the changes in serum FLC after autologous peripheral blood stem cell transplantation (PBSCT) in 19 patients. The majority of myeloma patients (18 of 19) undergoing PBSCT had a rapid fall in FLC concentrations. In all 11 of 19 patients with raised tumor FLC, it fell within 48 h following high-dose melphalan. In patients with monoclonal intact immunoglobulin, the tumor FLC fell quicker (median half-life 4.3 days) than the monoclonal intact immunoglobulin (median half-life 14 days). FLC recovery occurred after (13 of 19) or around the time of neutrophil engraftment (6 of 19). With a median follow up of 220 days post-transplant, 16 of 19 patients have a normal FLC ratio and 3 of 19 have an elevated tumor FLC/abnormal ratio. FLC assays provided a sensitive monitor of changes in tumor and non-tumor plasma cells after PBSCT. This assay is potentially valuable as a marker of chemosensitivity, as an indicator of residual tumor and indicated time to lymphocyte engraftment. Further follow-up is required to ascertain whether differences in the kinetics of FLC responses have any prognostic clinical utility.

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RB Pathology
Journal or Publication Title: LEUKEMIA & LYMPHOMA
Publisher: TAYLOR & FRANCIS LTD
ISSN: 1042-8194
Date: January 2006
Volume: 47
Number: 1
Number of Pages: 8
Page Range: pp. 21-28
Identification Number: 10.1080/10428190500254216
Publication Status: Published
URI: http://wrap.warwick.ac.uk/id/eprint/34259

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item View Item
twitter

Email us: publications@warwick.ac.uk
Contact Details
About Us